BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11529718)

  • 1. Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Xu G; Loftus TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
    J Org Chem; 2001 Sep; 66(18):5958-64. PubMed ID: 11529718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
    Casimiro-Garcia A; Micklatcher M; Turpin JA; Stup TL; Watson K; Buckheit RW; Cushman M
    J Med Chem; 1999 Nov; 42(23):4861-74. PubMed ID: 10579849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
    Cushman M; Casimiro-Garcia A; Williamson K; Rice WG
    Bioorg Med Chem Lett; 1998 Jan; 8(2):195-8. PubMed ID: 9871653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
    Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
    J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
    Xu G; Hartman TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
    Bioorg Med Chem; 2002 Feb; 10(2):283-90. PubMed ID: 11741777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
    Deng BL; Cullen MD; Zhou Z; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
    Bioorg Med Chem; 2006 Apr; 14(7):2366-74. PubMed ID: 16321539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
    J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
    Silvestri MA; Nagarajan M; De Clercq E; Pannecouque C; Cushman M
    J Med Chem; 2004 Jun; 47(12):3149-62. PubMed ID: 15163195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.
    Sakamoto T; Cullen MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
    J Med Chem; 2007 Jul; 50(14):3314-21. PubMed ID: 17579385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
    Cullen MD; Deng BL; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; Clercq ED; Cushman M
    J Med Chem; 2007 Oct; 50(20):4854-67. PubMed ID: 17803290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
    J Med Chem; 2005 Sep; 48(19):6140-55. PubMed ID: 16162014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
    Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
    Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel 2H-pyran-2-one derivatives as potential HIV-1 reverse transcriptase inhibitors.
    Defant A; Mancini I; Tomazzolli R; Balzarini J
    Arch Pharm (Weinheim); 2015 Jan; 348(1):23-33. PubMed ID: 25523431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
    Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
    J Med Chem; 2006 Aug; 49(17):5316-23. PubMed ID: 16913721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
    Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
    J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain.
    Xiong YZ; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Chem Biodivers; 2009 Apr; 6(4):561-8. PubMed ID: 19353537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
    Hoshi A; Sakamoto T; Takayama J; Xuan M; Okazaki M; Hartman TL; Buckheit RW; Pannecouque C; Cushman M
    Bioorg Med Chem; 2016 Jul; 24(13):3006-3022. PubMed ID: 27234889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.